ERYTECH welcomes new US and European investors Post author:admERY Post published:February 13, 2014 Post category:Newsroom ERYTECH was informed today that certain of its historical institutional investors have sold part of their holdings to new specialized life sciences investors in the United States and in Europe. You Might Also Like ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH November 7, 2014 ERYTECH to Host on September 22, 2020 Second Quarter 2020 Conference Call and Business Update September 16, 2020 ERYTECH reports positive Phase 2b data for eryaspase for the treatment of metastatic pancreatic cancer March 27, 2017
ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH November 7, 2014
ERYTECH to Host on September 22, 2020 Second Quarter 2020 Conference Call and Business Update September 16, 2020
ERYTECH reports positive Phase 2b data for eryaspase for the treatment of metastatic pancreatic cancer March 27, 2017